It comes as a solution for injection to be injected intravenously (into the vein) for over 35 minutes in adults and 1-4 hours in children. The drug should not be administered as intravenous push or bolus injection.
Atypical hemolytic uremic syndrome: In adults, 900 mg is administered weekly for four weeks followed by fifth dose of 1200 mg after another week; thereafter 1200 mg is administered once every two weeks. Dosage in children depends on their body weight.
Additional doses are required if the patient undergoes plasma exchange or is administered fresh frozen plasma infusion.
• Paroxysmal nocturnal hemoglobinuria (PNH) in which red blood cells (RBCs) are broken down resulting in anemia and decreased oxygen supply to the body.
Soliris
Dosage & When it is to be taken
Paroxysomal nocturnal hemoglobinuria: Intravenous dose of 600 mg is administered weekly for the first 4 weeks, followed by 900 mg 7 days later for the fifth dose; thereafter 900 mg is administered once every two weeks.Atypical hemolytic uremic syndrome: In adults, 900 mg is administered weekly for four weeks followed by fifth dose of 1200 mg after another week; thereafter 1200 mg is administered once every two weeks. Dosage in children depends on their body weight.
Additional doses are required if the patient undergoes plasma exchange or is administered fresh frozen plasma infusion.
When it is not to be taken (Contraindications)
Eculizumab is contraindicated in patients who are allergic to the drug, in patients with unresolved serious Neisseria meningitidis infection, or who have not been vaccinated against the infection, unless the benefit of the drug outweigh the risk of suffering from meningococcal infection.Drug Name : Eculizumab
Eculizumab is a monoclonal antibody, which is prescribed for two conditions:• Paroxysmal nocturnal hemoglobinuria (PNH) in which red blood cells (RBCs) are broken down resulting in anemia and decreased oxygen supply to the body.
Trade Names/Brand Names of Eculizumab
International :
Soliris
